The rich chemical and structural versatility of transition metal complexes provide numerous novel paths to be pursued in the design of molecules that exert particular chemical of physicochemical effects that could operate over specific biological targets.
Introduction
The rich chemistry of metal centers constitutes an opportunity for designing coordination complexes with biological and biomedical applications. [1] [2] [3] Metal complexes are chemically and structurally very versatile; the nature of the ligand and the metal ion can be chosen to endow complexes with diverse electronic, chemical, kinetic and photophysical properties. 2, 4 This versatility provides numerous novel paths to be pursued in the design of molecules that exert particular chemical or physicochemical effects that could operate over specific biological targets. 5, 6 However, biochemical processes in living organisms are very complex, with multiple interdependent connections. Therefore, basic understanding of the mechanisms of action and target sites of metal complexes in biological hosts are necessary before these compounds can eventually reach therapeutic applications. [4] [5] [6] [7] On the other hand, it is also currently recognized that the poor cell permeability of metallodrugs represents an important barrier for their therapeutic use. 8 Tackling this problem is considered a key area in modern medicinal chemistry, since it is crucial for the drug efficacy, but also for the control of adverse effects and to overcome drug resistance. [9] [10] [11] [12] Research efforts in the development of drug delivery systems have led to approaches useful to improve the efficacy of the existing metal complexes through enhancing their cellular uptake level and their targeted intracellular delivery. Besides, 3 another key point relies on addressing the metal complex to the tumor or tissue in a selective way through homing devices, thereby avoiding potential toxic side effects.
Among multiple approaches, conjugation of metal complexes to peptide scaffolds is emerging as a promising strategy to enhance their uptake properties, cell-selective internalization and site-selective delivery.
Considering this frame, the focus of this perspective lies on reviewing the recent advances on metallopeptide conjugates used for biomedical applications. Given the large literature on the synthesis and biological evaluation of these conjugates, the scope of this review has been restricted to those including a non-peptidic pendant metal complex or metal-binding ligand linked to a peptide scaffold. Therefore, studies on catalytically active metallopeptides or integrated de novo metallopeptide designs have been excluded. Details about metallopeptide catalysts were reviewed by Lewis 13 and interesting approaches involving metal-induced peptide self-assembly have been recently summarized by Tian and co-workers. 14 
Potential of metal complexes and peptide-based vectors: towards metallopeptides
Improving the selectivity and the therapeutic activity of the drugs is a major goal in the development of novel anticancer compounds. Even when several moleculartargeted drugs discriminate cancer cells from healthy cells, drug resistance and genetic mutations remain as key barriers in current cancer treatments. 11, 15 Bearing in mind these limitations, the targeting of biochemical alterations in cancer cells is one of the most promising strategies against drug resistance. A particularly interesting target element is the enhanced oxidative stress observed in cancer cells . 16 In biological systems reactive oxygen species (ROS) are generated through different pathways and its homeostasis is essential for the normal cell growth. 16, 17 However, ROS enhancement is generally associated to a disruption in redox homeostasis, especially as a result from disruption of mitochondrial functions. Hence, the possibility to target the redox balance in cancer cells has emerged as an effective strategy to pursue selectivity over normal cells. 16, 18 Mitochondrial and nuclear compartments are particularly important subcellular target sites. The delivery of ROS-interacting drugs to the former is especially interesting since mitochondria regulate the redox balance and the apoptotic cell death.
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Owing to their redox properties, transition metal complexes can directly interfere with the cellular redox chemistry by creating or interacting with ROS, or indirectly by binding to biomolecules involved in redox homeostasis. 4 This redox activity can be finely tuned by manipulating the oxidation state, electronics and redox properties of the complexes. 2 Indeed, a wide variety of transition metals can reach variable oxidation states and are susceptible to engage in reactions with ROS. The ligand can also play a key role in the expected biological activity because it can recognize and interact with the target site, and recognition may trigger a redox response. This control over the redox properties of the transition metal complexes can actually help avoiding undesirable toxicity in other biological sites. 16, 17, 19 Despite of the interesting properties that offer metallodrugs in current biomedical field, their enhanced and targeted delivery into the cell is challenging. In first place, little is known about their speciation in biological systems and their real involvement in cellular redox processes. Moreover, it should be taken into account that transition metal complexes can suffer drastic alterations inside cellular environments;
ligand exchange or degradation and redox changes may occur, and some of these changes can result in release of the metal. 5 If so, severe difficulties arise when elucidating mechanism of action of these metal-based agents in cellular redox homeostasis. Of note, Sadler and Lippard groups recently reported excellent reviews where the direct and indirect involvement of redox chemistry in the activity of a wide variety of metal-based anticancer drugs is discussed. 4, 5 The conjugation of transition metal complexes to effective targeting vectors when pursuing an improved cellular uptake and targeted recognition is depicted as an excellent approach for taking advantage of ROS enhancement at specific sites. In this regards the conjugation between metal complexes and a functional peptide vector can be regarded as a versatile and powerful strategy. In fact, peptide-based approaches have been considered as useful tools to enhance cell entry and to deliver biologically active cargoes at the subcellular level. 20, 21 The so-called cell-penetrating peptides (CPPs) are short cationic and amphipathic sequences, containing less than 30 amino acids, which are able to cross the cellular membrane. [22] [23] [24] These peptides have shown excellent
properties for the intracellular delivery of a wide variety of drugs through the cell membrane. [24] [25] [26] In the similar vein, other peptide sequences such as mitochondriapenetrating sequences (MPPs) 27 or more specific targeting sequences for nuclear (NLS) 5 and mitochondrial delivery (MLS) allow a broad range of possibilities to gain effective intracellular trafficking. 28 On the other hand, targeted drug delivery approaches are required to obtain selectivity against diseased tissues. 9 Among target vectors for cancer cells, homing peptides (HPs) are employed to obtain a selective interaction with cellsurface receptors that are overexpressed in cancer cells. 20, 29 There are generally two kinds of HPs: (i) those with the capacity to recognize specific phenotypes but without cell-penetrating properties, and (ii) those which recognize the targeted cell but are also able to internalize inside the cell. The latter, also called cell-penetrating-homing peptides (CPHPs), are particularly challenging due to their suitability to be used as selective delivery vectors with reduced side effects. 20, 30 However, the use of vectorized transition metal complexes as drugs is not free of problems. On the one hand, it is still difficult to determine to what extent the modulation of cellular redox processes is involved in the activity of transition metal complexes. On the other hand, the direct quantification of the cellular uptake is often controversial and complementary monitoring techniques are highly required. These limitations and the lack of clear knowledge of how the whole conjugate would work in a cellular environment constitute major problems when designing highly efficient systems based in transition metals.
Metallopeptides: Synthetic approaches
The preparation of metallopeptides is challenging because of the chemical functionality of peptides and the lability of metal complexes. Researches have taken advantage of the solid-phase peptide synthesis (SPPS) to prepare these compounds.
These SPPS procedures were reviewed by Dirscherl and König in 2008. 31 In particular, different approaches have been envisioned to obtain these conjugates using SPPS. One of them involves the attachment of the metal complex to the resin-bound peptide. In this strategy the use of an excess of the metal complex is required and, moreover, the resulting metallopeptide has to be stable to the final cleavage step from the resin.
Alternatively, the metal complex can be linked in solution to the peptide which has been previously prepared on solid-phase. This protocol is especially useful for metallopeptides incorporating a very sensitive metal complex. Another versatile approach involves the coupling of the ligand moiety to the resin-bound peptide, The conjugation of metal complexes to a peptide sequence through amide bond formation was first described by Metzler-Nolte group in pioneering studies in this field.
On the one hand, this group prepared metallopeptides that incorporate a metallocene bound to a nuclear localization sequence (NLS). These metallocene-NLS conjugates were synthesized by coupling cobaltocenium or ferrocene carboxylic acid to the resinbound NLS, followed by their cleavage from the resin ( Figure 1a ). 32, 33 On the other hand, these authors also reported the synthesis of metallopeptides incorporating a NLS and a complex of Zn(II) or Cu(II) with a modified N,N -bis(2-picolyl)amine (bpa) ligand ( Figure 1b ). 34 The bpa-NLS metal binding peptide was obtained using standard SPPS methods, whereas the metalation step was performed in solution. These early studies opened up the possibility to deliver biologically important metal ions at the subcellular level.
Later, this methodology was used by other authors to prepare new metallopeptides. For instance, Artaud and cowokers described the synthesis of metallopeptides by anchoring a tris(2-pyridylmethyl)amine (tpa) or a 2,2′-dipicolylamine (dpa) ligand to a resin-bound peptide followed by cleavage and metallation with a Zn(II), a Co(III) or a Cu(II) salt ( Figure 1c) . 35, 36 The peptides used in this study were the short antimicrobial peptide analogue RWRW-OBn and the efflux pump modulator PAβN. Recently, it has been reported the synthesis of Zn(II) and Cu(II) metallopeptides based on PyTACN and (S,S')-BPBP tetradentate aminopyridine ligands in the context of ROS generation in cancer therapies (Figure 1d ). 37 The preparation of these metallopeptides relied on the solid-phase synthesis of the corresponding metal binding peptide, subsequent cleavage from the solid support and metallation with a Zn(II) or Cu(II) salt. These two metal binding peptides were obtained following two different approaches. The synthesis of the metal binding peptide 7 incorporating a PyTACN ligand required the previous preparation of this ligand in solution, which was then coupled to the resin-bound peptide. In contrast, the (S,S')-BPBP aminopyridine ligand was assembled to the peptidyl resin in a stepwise manner, including the attachment of a nicotinic acid derivative followed by derivatization with the corresponding secondary amine. complexes. 39 They observed that these compounds protect neurons from amyloid β 8 toxicity. Metzler-Nolte and co-workers also reported the use of click chemistry in standard SPPS for the conjugation of an azidomethylruthenocene moiety to resin-bound alkynyl peptides (Figure 2b ). 40 This report shows the suitability of this ruthenocene moiety as a convenient building block to be introduced into peptide sequences under mild conditions. The same authors described a silyl-based linker useful for the synthesis of C-terminal acetylene-derivatized peptides which they reacted afterwards with azidomethylferrocene in solution to obtain the corresponding ferrocene-peptide conjugates ( Figure 2c) . 41, 42 The usefulness of the CuACC and also of the Pd-catalyzed Sonogashira crosscoupling for the preparation of metallopeptides has been explored by Schatzschneider group (Figure 2d ). 43 Towards this end, a tris(pyrazolyl)methane (tpm)-alkynyl complex In recent studies, Vázquez and co-workers took advantage of the standard SPPS procedures and of the intrinsic chirality of peptides to achieve the stereoselective formation of chiral metallopeptides. This work was prompted by the crucial role of chirality in recognition processes of biological targets. 45 For this purpose, following standard SPPS protocols, the authors synthesized metal binding peptides incorporating two bpy coordinating units joined by three to five amino acids that include a [D/L]-ProGly β-turn-promoting moiety (Figure 3a) . After the cleavage from the resin and metallation with Zn(II), Co(II) and Ni(II) salts, the corresponding chiral metallopeptides were obtained. This methodology was further extended to the preparation of chiral metallopeptide helicates with DNA-binding properties (Figure 3b ). 46 The corresponding peptidic ligands were synthesized on solid-phase and contained six bpy units arranged metallopeptides (Figure 3c and 3d) . 47 The synthesis of the bis-chelating peptide ligands and also their metalation were performed on solid-phase. This methodology easily allowed the incorporation of an octaarginine tail to these DNA-binding metallopeptides to promote their cellular uptake. 47 reported by Vázquez and co-workers.
Peptide-based delivery of metal complexes
Peptide-based delivery of bioactive metal complexes is specially challenging when seeking an improved stability, cell selectivity and a targeted subcellular localization. Therefore, the improvement in the cellular uptake properties of these compounds could lead to highly efficient metal-based systems where the final targeting and function is defined in the cellular environment. The examples covered in this (Figure 4a ). 48 The results established that this CPP efficiently enhanced the cell internalization of the Rh 3+ complexes and facilitated their nuclear localization.
Although the presence of the CPP increased the non-specific binding to DNA, it did not notably influence the site specificity of the photocleavage. Taking advantage of these cellular uptake studies, Barton group evaluated the cell-penetrating properties of luminescent Ru(II) dppz complexes conjugated to D-octaarginine or to RrRK, and compared them with those of the corresponding fluorescein-labeled metallopeptides (Figure 4b) . 49, 50 This work emphasizes the importance of exploring the fluorophore effect, since it was noticed that the cellular uptake properties of the non-labeled metallopeptide differed significantly from those of the labeled one.
CPPs based on arginine have also been conjugated to other metal complexes to search for an enhanced biological activity. Sadler and Brabec groups reported the conjugation of the Os(II) arene anticancer complex [(η 6 -bip)Os(pico)Cl] (bip = biphenyl, pico = picolinate) to an octa-or a pentaarginine sequence (Figure 4c ). 51 Despite the presence of a CPP did not improve the cytotoxic activity of the parent metal complex in cancer cells, 52, 53 it significantly enhanced its cellular uptake and its DNA binding. In support to these targeted delivery works, Keyes group exploited the capacity of Ru(II) polypyridyl peptide conjugates as probes for cell imaging. 54, 55 Metallopeptides incorporating other CPPs such as Tat [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , sC18 or Penetratin have also been described. For instance, Keppler group reported the conjugation of a Pt(IV) analogue of oxaliplatin prodrug to the Tat 47-57 peptide (YGRKKRRQRRR-NH 2 ). 56 The resulting mono-and difunctionalized conjugates were found to be more cytotoxic than the parent platinum complex. Similarly, Gasser group conjugated a luminescent Re(I) tricarbonyl polypyridine-based complex to the myristoylated Tat [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] peptide via a CuACC reaction (Figure 5a) . 57 This conjugation improved the cellular uptake and the cytotoxicity of the metal complex, being the resulting metallopeptide as cytotoxic as cisplatin against HeLa cells. Moreover, Neundorf and co-workers reported the attachment of cymantrene (CpMn(CO) 3 ) carboxylic acid derivatives to the cellpenetrating peptide GLRKRLRKFRNKIKEK-NH 2 (sC18), which was previously identified by the same authors (Figure 5b) . 58 (Figure 5c ). 59 The resulting conjugates retained the iron binding abilities and the antioxidant properties of DFO, and showed an enhanced cell internalization capacity. Since DNA is the cellular target of many bioactive metal complexes, these compounds have been appended to a nuclear localization sequence (NLS). These sequences are small peptides that enable the active transport of drugs into the cell nucleus. Hence, the conjugation of a metal complex to a NLS constitutes a feasible approach to obtain a subcellular localization of these compounds. As previously mentioned, Metzler-Nolte group reported metallopeptides incorporating a metallocene covalently bound to a NLS (Figure 1a) . 32, 33 It was found that whereas the metallocene moiety facilitates the cellular internalization, the NLS plays a key role in the nuclear localization of the conjugate. Moreover, these metallopeptides resulted to be non-toxic.
Similarly, Keyes group achieved the selective delivery to the cell nucleus of two , by conjugating them to the NLS peptide VQRKRQKLMP-NH 2 , which derives from the transcription factor NF-κB. 60 Moreover, the unique properties of transition metal complexes have been also employed for monitoring the intracellular redox status. Since in mitochondria the redox balance plays an important role, the vectorization of a metal complex into this organelle has been used to monitor changes in oxygen concentration as well as ROS generation.
In this context, Keyes and co-workers reported the mitochondrial vectorization of a dinuclear Ru(II) polypyridyl complex. 61 selectivity of these complexes (Figure 6b ). 62 The Re-NLS conjugate significantly accumulated into the cell nucleus and both conjugates induced DNA damage via production of 1 O 2 , as shown by DNA photocleavage studies. The activity of these conjugates was improved by using a photocaged strategy. 63 An o-nitrophenyl photolabile linker (PLPG) was incorporated between the Re(I) complex and the corresponding peptide sequence (Figure 6c ). Re-NH 2 was selectively photoreleased from Re-PLPG-NLS and Re-PLPG-bombesin conjugates and, upon irradiation, both metallopeptides showed IC 50 values similar to those of cisplatin against HeLa cells.
Following a similar approach, the same group described the photocaging of a cytotoxic ferrocenyl derivative (Fc-NH 2 ) which acts as a ROS-generation catalyst in cancer cells.
This photocaging was achieved with an o-nitrophenyl or an o-nitrobiphenyl photolabile protecting group (PLGP) and the photocaged conjugates were further linked to the MLS CrFK-NH 2 (Figures 6d and 6e) . 64 Both metallopeptides were less cytotoxic than Fc-NH 2 in the dark and, upon irradiation, the conjugate incorporating the o-nitrobiphenyl cage was the most active against the cancer cell lines tested. Besides, upon irradiation, the two conjugates displayed poor cytotoxic effects in non-malignant cells. 
Cell-selective delivery of metal complexes for anticancer therapy
In order to overcome harmful side-toxic effects of metal-based anticancer complexes, cell-targeting strategies could be also rationally designed using peptides as site-selective delivery devices. Selected recent examples covering this concept based on the conjugation of metal complexes to cell-penetrating-homing peptides (CPHPs) are described in the following lines.
Proof of concept of this approach can be found in work by Lippard and co- In an effort to overcome drug resistance, especially towards the multiple antiapoptotic signaling pathways that hamper the biological action of conventional chemotherapeutics, the Ang group has recently reported the design of a biphasic mode of action based on Pt(IV)-conjugates. [75] [76] [77] The authors introduced a HER2-targeted Pt prodrug design, which consists on the conjugation of cisplatin and oxaliplatin to the AHNP (anti-HER2/neu peptide) targeting peptide moiety. 78 In light of this, this design is meant to selectively internalize through HER2 expressing cells and further induce a rapid killing through targeted necrosis instead of apoptosis, thus avoiding apoptosis resistance mechanisms. The Pt(IV) prodrug scaffolds were effectively conjugated to a 22 are meant to extend their safety as well as their efficacy while pursuing very low toxicity. 22, 79 Thus, given the biologically potential of metallopeptide conjugates, undoubtedly these designs will attract more attention and play a key role in synthetic chemistry as well as in medicinal chemistry in the coming years.
